The PARAMOUNT trial: A phase III randomized study of maintenance pemetrexed versus placebo immediately following induction first-line treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small cell lung cancer

Reviews on Recent Clinical Trials

Volumn 8, Issue 1, 2013, Pages 23-28

  Gridelli, Cesare ^a   Maione, Paolo ^a   Rossi, Antonio ^a  

^a S G MOSCATI HOSPITAL   (Italy)

Author keywords

Advanced NSCLC; Cisplatin; Continuation maintenance; Erlotinib; Pemetrexed; Switch maintenance

Indexed keywords

CISPLATIN; DEXAMETHASONE; ERLOTINIB; FOLIC ACID; PEMETREXED; PLACEBO; PLATINUM;

ADVANCED CANCER; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; DRUG SAFETY; FATIGUE; FERILE NEUTROPENIA; HISTOPATHOLOGY; HUMAN; INDUCTION CHEMOTHERAPY; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84874902168     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/15748871112079990040     Document Type: Article

References (19)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Govindan R, Page N, et al. Changing epidemiology of small cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic and end results database. J Clin Oncol 2006; 24: 4539-4544.
3. Mountain C. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-1717.
4. Socinski MA, Crowell R, Hensing TE, et al. Treatment of nonsmall cell lung cancer: stage IV: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest; 132 (suppl. 3): 277S-289S.
5. D'Addario G, Felip E. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 (suppl. 4): iv68-iv70.
6. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27: 6251-6266.
7. Gridelli C, De Marinis F, Di Maio M, et al. Maintenance treatment of advanced non-small-cell lung cancer: results of an international expert panel meeting of the Italian association of thoracic oncology. Lung Cancer 2012; 76: 269-279.
8. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, doubleblind, phase 3 study. Lancet 2009; 374: 1432-1440.
9. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14: 253-263.
10. Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MCJMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 2012; 13: 292-299.
11. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11: 521-529.
12. European Medicine Agency. Committee for medicinal products for human use (CHMP). Summary of opinion (post authorisation): Tarceva. Available at http://www.ema.europa.eu/pdfs/human/opinion/TarcevaII_8608010en.pdf Accessed: April 25, 2010.
13. Food and Drug Administration. Highlights of prescribing information: Tarceva. Available at http://www.accessdata.fda.gov/drugsatfda_ docs/label/2010/021743s14s16lbl.pdf Accessed: April 25, 2010.
14. Paz-Ares L, De Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13: 247-255.
15. Paz-Ares L, De Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30: suppl abstr LBA7507.
16. Gridelli C, De Marinis F, Pujol JL, et al. Safety, resource use, and quality of life results from PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately following induction treatment with pemetrexed-cisplatin for advanced nonsquamous nonsmall cell lung cancer. J Thorac Oncol 2011; 6 (suppl 6): S323 (14 World Conference on Lung Cancer-Amsterdam, July 3-7, 2011).
17. Azzoli CG, Temin S, Aliff T, et al. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011; 29: 3825-31.
18. Jassem J. Maintenance chemotherapy in advanced non-small cell lung cancer. Lancet Oncol 2012; 13: 217-218.
19. Klein R, Wielage R, Muehlenbein C, et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thorac Oncol 2010; 5: 1263-72.